Insulet/PODD

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Insulet

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.

Ticker

PODD

Sector

Healthcare

Trading on

NASDAQ

Industry

Health Care Equipment and Supplies

Headquarters

Acton, United States

Employees

3,000

Insulet Metrics

BasicAdvanced
$14B
Market cap
59.51
P/E ratio
$3.31
EPS
0.99
Beta
-
Dividend rate
$14B
0.99
3.743
2.478
177.172
182.092
7.66%
6.74%
36.18%
59.51
7.73
17.46
21.55
100.75
30.17%
38,259.20%
22.92%
196.55%

What the Analysts think about Insulet

Analyst Ratings

Majority rating from 23 analysts.
Buy

Insulet Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
11.65% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$442M
-13.36%
Net income
$52M
-50.15%
Profit margin
11.65%
-42.50%

Insulet Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 87.90%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.38
$0.71
$1.40
$0.73
-
Expected
$0.26
$0.40
$0.66
$0.39
$0.56
Surprise
44.52%
76.54%
112.99%
87.90%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Insulet stock?

Insulet (PODD) has a market cap of $14B as of July 03, 2024.

What is the P/E ratio for Insulet stock?

The price to earnings (P/E) ratio for Insulet (PODD) stock is 59.51 as of July 03, 2024.

Does Insulet stock pay dividends?

No, Insulet (PODD) stock does not pay dividends to its shareholders as of July 03, 2024.

When is the next Insulet dividend payment date?

Insulet (PODD) stock does not pay dividends to its shareholders.

What is the beta indicator for Insulet?

Insulet (PODD) has a beta rating of 0.99. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Insulet stock

Buy or sell Insulet stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing